Date: Tuesday, November 8Time: 6:30 - 8 p.m.Format: VirtualRegistration: RequiredRSVP LinkDownload the program (PDF)
Trudi Denoon ’08P, ’12GP, ’20Ph.D.
Regulatory Toxicologist Consultant
Gad Consulting Services[email protected]
Trudi Denoon ’20Ph.D. is a Regulatory Toxicologist Consultant at Gad Consulting Services (GCS) in Raleigh, NC. She earned a B.S. and M.S. degree in Toxicology, and a Ph.D. in Pharmaceutical Sciences, from St. John’s University’s College of Pharmacy and Health Sciences in Queens, NY. Her doctoral research, under the tutelage of Sue M. Ford, Ph.D., DABT, Associate Professor, Department of Pharmaceutical Sciences, provided extensive academic training and research experience in multiple disciplines such as renal toxicology, bioenergetics, and metabolic reprogramming.
As a result of her academic work at St. John’s University, Dr. Denoon served as a postdoctoral fellow at the Rogosin Institute in New York, NY, from December 2019 to June 2021. Her research focused on developmental biology and explored the role of bioenergetics and metabolic reprogramming of stem cells during different phases of directed differentiation. Her academic pursuits focused on improving the quality of kidney derived organoids that would make them a viable alternative for organ replacement therapy and a useful tool for toxicological screening.
At GCS, her current area of expertise focuses on evaluating drug impurities for potential toxicity including mutagenicity, qualification of impurities in drug products and substances, performing toxicological risk assessment for leachables and extractables, and establishing occupational exposure limits. Additionally, her other roles include editing and authoring book chapters for the Encyclopedia of Toxicology.
Previously, Dr. Denoon was awarded First Place at the 2018 Student Research Month at St. John’s University. She was also the recipient of the Certificate of Academic Excellence for outstanding achievement in completing the Doctor of Philosophy at St. John’s University.
Dr. Denoon is an alumna and former participant of the New York Academy of Sciences’ Science Alliance Leadership Training program. She served as a graduate student representative for the Ethical, Legal Forensics and Specialty Section of the Society of Toxicology (SOT) from May 2017 to May 2020. She was also a member of the Mid-Atlantic Society of Toxicology and the Graduate Student Leadership Committee, Society of Toxicology (May 2017–May 2020). She is currently a member of subgroups, including SOT, Toxicologists of African Origin, Women in Toxicology, the Medical Device Combination Product Specialty Section, and the Regulatory and Safety Evaluation Specialty Section. She has authored one publication and two published abstracts.
Dave Gossai ’05GP, ’08Ph.D.
Director of Safety
Dave Gossai ’05GP, ’08Ph.D., joined L’Oréal USA in July of 2012. He leads the product safety group within skin care. He is currently leading a group of five toxicologists, each of whom is responsible for individual skin care brands within L’Oréal. He is engaged in various external collaborations, including with the Personal Care Products Council and Sunscreen Consortium.
With respect to his roles, Dr. Gossai is responsible for ensuring the safety of individual ingredients and formulations that will be marketed to the consumer. He is responsible for strategically performing the necessary in silico, in vitro, and human clinical trial programs to support the safe use of the ingredients and formulations.
Prior to L’Oréal, Dr. Gossai worked at the Medical Education Institute and Avon Products, Inc. During his one-year stint at the Medical Education Institute, he wrote scientific presentations for medical doctors. These presentations were to inform the medical community of the drugs used, their efficacy, and possible side effects. Following this time, Dr. Gossai spent the next eight years at Avon Products, Inc., where he was responsible for ingredient and formulations review and approval. He has experiences in in-silico modeling, in vitro testing, and human clinical evaluation.
Nathalie Jean-Charles ’07P, ’11GP
Molecular Laboratory Manager
P4 Clinical, LLC
Nathalie Jean-Charles ’07P, ’11GP earned her B.S. degree in Toxicology, with minors in Chemistry and French, at St. John’s University in 2007. She went on to complete a M.S. degree in Toxicology at St. John’s in 2011.
Ms. Jean-Charles is a molecular laboratory manager at P4 Clinical, LLC, where she uses her expertise as a scientist specializing in molecular genetics and the high-throughput detection of molecular biomarkers in the detection of infections, cancer, and genetic diseases. She is involved with design study metrics of all molecular laboratory-developed tests to improve testing sensitivity and accuracy.
Ms. Jean-Charles previously worked with the US Department of Homeland Security in the early detection of select agents that can be used in bioterrorism. During her time at the department, she developed and managed QA/QC programs for molecular testing.
Andrea DeSantis Rodrigues, Ph.D., DABT ’05P
Andrea DeSantis Rodrigues, Ph.D., DABT ’05P graduated from St. John’s University’s College of Pharmacy and Health Sciences with a bachelor’s degree in Toxicology in 2005. During her undergraduate studies at St. John’s, she was Vice President of Tau Omega Chi and worked with Blase C. Billack, Ph.D., Professor, Department of Pharmaceutical Sciences, on the “Effects of Distamycin A and Mechlorethamine on Yeast Cells.”
Dr. Rodrigues went on to earn her Ph.D. in Toxicology from Rutgers University/University of Medicine and Dentistry of New Jersey’s Joint Graduate Program in Toxicology (New Brunswick, NJ) in 2011. Her dissertation, “Countermeasures Against Vesicant-Induced Corneal De-adhesion,” was under the advisement of Marion Gordon, Ph.D., Associate Professor of Pharmacology and Toxicology, Rutgers University's Ernest Mario School of Pharmacy, Environmental and Occupational Health Sciences Institute. She has been a Diplomate of the American Board of Toxicology since 2015, has published research in peer-reviewed journals, and serves as a peer reviewer for ophthalmology and toxicology journals
Dr. Rodrigues is currently a Senior Principal Research Scientist at AbbVie in Irvine, CA, where she mainly works as a preclinical safety representative on pharmaceutical development project teams, mainly focused on eye care therapeutics and aesthetic therapies. She was previously the Director of Toxicology and Head of Nonclinical Development at PYC Therapeutics (San Diego, CA) where she helped develop oligonucleotide-based therapies for inherited retinal diseases, and was also a Managing Scientist at ToxStrategies, Inc. (Mission Viejo, CA), a toxicology-focused consulting firm.
Dr. Rodrigues started her career after graduate school as a Toxicology Scientist at Allergan LLC, and gradually moved into the role of Associate Director of Toxicology while gaining expertise in regulatory toxicology for various drug development programs, the animal care and use committee, and drug impurity guidance and assessments.
Dr. Rodrigues has been an active member of the Society of Toxicology since 2008 and was a former Student Representative for the In Vitro and Alternative Methods Specialty Section. She was a Councilor and is the current Vice President of the Ocular Toxicology Specialty Section.
Date: March 10
Time: 5–6 p.m.Program (PDF)
Lee D. Fiebert ’09Pharm.D., M.B.A., BCPS, CPHQ
Senior Assistant Vice President of Business Operations andSenior Corporate Health Project AdvisorNYC Health + Hospitals
Dr. Fiebert earned his Doctor of Pharmacy degree from St. John’s University in 2009 and his M.B.A. in health services management from Hofstra University. He completed a PGY-1 pharmacy residency at Northwell Health’s Long Island Jewish Medical Center and a PGY-2 health-system pharmacy administration residency at the Lebanon VA Medical Center.
At NYC Health + Hospitals, he is responsible for the development and integration of initiatives, services, and programs from the Office of Business Operations into the health system. Dr. Fiebert is a board-certified pharmacotherapy specialist and a certified professional in health-care quality.
Eric La ’13Pharm.D., BCPS
Expert Systems Analyst (Sunrise Clinical Manager Chemotherapy)Allscripts Healthcare Solutions, Inc.
Dr. La graduated with his Doctor of Pharmacy degree from St. John’s University’s College of Pharmacy and Health Sciences in 2013 and completed a PGY-1 pharmacy residency at Northwell Health’s Long Island Jewish Medical Center. After residency, he worked at Northwell Health’s Huntington Hospital as a Clinical Pharmacy Coordinator.
Currently, he is an Expert Systems Analyst on the Sunrise Clinical Manager Chemotherapy team for Allscripts Healthcare Solutions, Inc. They provide health-care informatics support to Northwell Health’s ambulatory cancer centers.
Mervyn Richardson ’92P, ’94Pharm.D.
Clinical Pharmacist, Critical Care/Application Service ProviderWhite Plains Hospital
Dr. Richardson entered the pharmacy profession in 1983 after graduating with a diploma in Pharmacy from the College of Arts, Science and Technology in Kingston, Jamaica. Subsequently, he earned both his Bachelor of Science in Pharmacy and his Doctor of Pharmacy degrees from St. John’s University in 1992 and 1994, respectively.
Upon graduation, Dr. Richardson accepted a pharmacist position at St. Barnabas Hospital, where he held several positions, including Clinical Coordinator, before being appointed Assistant Director of Pharmacy in 1998. He has held several academic appointments, including adjunct clinical faculty positions, at both Touro College of Pharmacy and LIU Pharmacy (The Arnold & Marie Schwartz College of Pharmacy and Health Sciences).
Date: Wednesday, November 18Time: 4:30–6 p.m.
Senior Associate Director, Global Pharmacovigilance
Victoria Bartasek, R.Ph. ’97P, is a Senior Associate Director, Global Pharmacovigilance, at Boehringer-Ingelheim. In this role, Ms. Bartasek has led a cross-functional global team focused on improving processes and systems related to the handling of serious adverse events from clinical trials and ensuring global regulatory compliance related to clinical trial processes within global pharmacovigilance. She currently leads a team responsible for the coordination, review, and operational approval of all marketing and patient support programs worldwide.
Prior to Boehringer-Ingelheim, Ms. Bartasek spent 14 years at Pfizer Inc. in Global Pharmacovigilance, where she held various positions with increasing responsibility, most recently as Director, Worldwide Safety and Regulatory Operations, where she led the initiative for the global safety database transition. She began her pharmaceutical career at Novartis as a Clinical Safety Scientist and is a registered pharmacist by trade. She graduated from St. John’s University’s College of Pharmacy and Health Sciences and also holds a Master of Business Administration degree in finance and marketing from Dowling College.
Manager II, Specialty Channel Strategy
Market Access -Trade and Distribution - US Specialty
Kenneth Joseph, Pharm.D., is currently a Specialty Channel Strategy Lead, Market Access, Trade and Distribution, for multiple Specialty Portfolio products at AbbVie Inc. In this role, he is responsible for implementing innovative clinical programs and executing business strategies to increase patient access and adherence, as well as to enhance the patient journey. The programs are operationalized in selected pharmacies and have a health informatics component that is utilized to help strategize from a business intelligence perspective.
Prior to AbbVie, Dr. Joseph worked at Walgreens in a vast array of different leadership capacities ranging from, but not limited to, Community Engagement Lead, University Relations, Pharmacy Management, and most recently at Walgreens corporate headquarters in Deerfield, IL, supporting the company’s multichannel specialty pharmacy model across the nation in their Biopharmaceutical Business Development Division.
After a 12-year tenure with Walgreens, he left to pursue a new adventure and joined AbbVie Inc. in late 2018. Dr. Joseph obtained his Doctor of Pharmacy degree from Florida Agricultural and Mechanical University where he was elected, most notably, Mr. College of Pharmacy and Pharmaceutical Sciences, Pharmacy Student Council President, and Graduate Student Body President. He is also a member of the Delta Iota chapter of Kappa Psi Pharmaceutical Fraternity, Inc., as well as the Upsilon Psi chapter of Omega Psi Phi Fraternity, Inc.
Dr. Joseph still actively mentors students as a career coach and guest lecturer at Florida Agricultural and Mechanical University, the University of Florida, the University of Illinois at Chicago (UIC), and several other institutions. He is also currently completing his M.B.A. at UIC’s Liautaud Graduate School of Business, where he also sits on the Board of Directors for the Center for Supply Chain Management and Logistics.
Executive Director, US Commercial Compliance
Allergan, an AbbVie company
Lance Moore, R.Ph., J.D. ’99P, ’04L graduated cum laude in 1999 from St. John’s University’s College of Pharmacy and Allied Health Professions with a Bachelor of Science degree in Pharmacy and a minor in business. He has been a registered pharmacist since 1999. While at St. John’s, he interned at the American Pharmacists Association (APhA) and was a member of various clubs and organizations, including the men’s lacrosse team, President’s Society, and the APhA Academy of Student Pharmacists. He graduated from St. John’s School of Law in 2004 and was admitted to the New York Bar in 2005.
Mr. Moore worked for Genovese Drug Stores, Inc. from 1995 to 1999 in various roles as a pharmacist, graduate student, intern, and technician. After graduating from pharmacy school, he worked as a sales representative for Eli Lilly and Company from 1999 to 2004, where he educated physicians on products in the diabetes and neuroscience diseases states while earning sales awards such as Presidents Council, Executive Council, Leadership Circle, and District Peer Award.
After graduating from law school, Mr. Moore took a position at Pedinol Pharmacal Inc., a small pharma company on Long Island, NY, as the Regulatory Affairs Director and Legal Executive from 2005 to 2012. His responsibilities ranged from handling legal issues such as contracts and litigation; regulatory issues such as US Food and Drug Administration communications, reporting, and approvals; and compliance issues such as internal policy creation and training.
He transitioned to a focused compliance role in 2012 at Allergan, an AbbVie Inc. company (formerly, Actavis and Forest Labs). This role supported sales, marketing, and commercial teams as a business partner to make smart business decisions consistent with company policy, government regulation, and the law. A large focus included employee training, monitoring, and policy development. Recently, the compliance team was recognized as the 2020 Global Function Team of the Year and compliance members were included on the 2020 General Medicine Cross-Functional Team of the Year.
Associate Medical Director
Allen Sieh ’19Pharm.D. is currently an Associate Medical Director at ProHEALTH Care. Dr. Sieh is the medical lead for several medical affairs and medical information projects in the cardiology/nephrology space. He has also played a key role in the development of various peer-to-peer educational materials for a multiple sclerosis treatment. Additionally, he has experience supporting a drug launch by contributing to the development of advisory board materials for a wet age-related macular degeneration treatment.
Date: Tuesday, November 9Virtual View the program PDF here
The event is sponsored by the Office of the Dean in the College of Pharmacy and Health Sciences and Tau Omega Chi. It is supported, in part, by the Society of Toxicology (SOT) through the Mid-Atlantic SOT Regional Chapter.
Research Institute for Fragrance Materials (RIFM)
Dr. Sadekar joined the Research Institute for Fragrance Materials in January of 2018. She is the lead for Local Respiratory Toxicity Safety Assessment and its research program. She is engaged in various collaborations across the scientific community with academic, governmental, and industrial peers to develop the RIFM’s Respiratory Sciences program.
As a part of the process team, Dr. Sadekar is also actively involved with various process development projects within RIFM. Communicating scientific projects to a broad audience is part of her role and responsibilities at RIFM. Dr. Sadekar has practical training working with in vitro and in vivo models (2009–17), and is experienced in teaching and leading the Biomedical and Human Anatomy and Physiology laboratories at St. John’s University (2011–16).
She is an active member of the Society of Toxicology (SOT), where she participates in several specialty sections and special interest groups. She served as the Counselor for the SOT’s Ethical, Legal, Forensic, and Societal Issues Specialty Section between 2019 and 2021. The Regulatory and Safety Evaluation Specialty Section at SOT recognized Dr. Sadekar for her doctoral work investigating the toxicity profile of Ras Sindoor, an Indian Ayurvedic medicine used as an alleged therapeutic agent (2017).
She has co-authored many peer-reviewed publications and serves as a reviewer for scientific journals. Dr. Sadekar has served as the newsletter editor for the American Society for Cellular and Computational Toxicology since 2019. Her skillsets include human health risk assessment, and her research interests are associated with developing alternative methods to animal studies, using in vitro and in silico tools.
Dr. Sadekar has served on the scientific advisory panel focusing on the US Environmental Protection Agency (EPA)’s Federal Insecticide, Fungicide, and Rodenticide Act (December 2018) and as a Peer Reviewer for the EPA’s Office of Chemical Safety and Pollution Prevention (October 2020). She was a member of the Institutional Animal Care and Use Committee at St. John's University (2016–17), volunteered for service on the Women in Toxicology Awards Committee (2016), and has served as the Mercury Toxicity Poster Session Chair at the Society of Toxicology Annual Meeting (2016).
Penn State College of Medicine
Dr. Sunilkumar is a postdoctoral scholar in the Department of Cellular and Molecular Physiology at Penn State College of Medicine. He began his academic career majoring in pharmaceutical sciences and earned his Ph.D. in pharmaceutical sciences with a concentration in toxicology from St. John’s University under the mentorship of Sue M. Ford, Ph.D.
A result-oriented scientist and an innovative leader with more than 10 years of research experience in academia, Dr. Sunilkumar has multiple peer-reviewed manuscripts and has secured $20,000 in research funding.
In his current role, he studies diabetes pathophysiology and the underlying mechanisms of development and progression of diabetes-associated pathologies. His expertise in cell signal transduction mechanisms with a focus on mTOR and cyclic-AMP-mediated signaling pathways also aids in developing better in vitro models for studying disease pathophysiology.
Dr. Sunilkumar’s duties involve planning and coordinating studies, as well as writing and editing manuscripts and research grants. His work on a novel hypothesis derived from stress protein-influenced retinal pathologies has been awarded a research grant by the Children’s Miracle Network.
As a graduate student, his research focused on renal cell phenotype changes influenced by culture media composition. His experience as a teaching fellow at St. John’s has been conducive in his development as an academician. The collaborative environment fostered both during his graduate work and currently has allowed him to be actively involved in the scientific community mentoring junior scientists in toxicology and molecular physiology.
Health Program Coordinator
New York State Department of Health, Division of Epidemiology
Ms. Oxford is currently the Health Program Coordinator for the New York State Department of Health’s Division of Epidemiology. She earned her bachelor’s degree in toxicology from St. John’s University in 2013, and went on to pursue her master’s in public health at Kaplan University.
She began the COVID-19 pandemic working at the local level of a county health department performing case investigation and contact tracing; she also assisted setting up their drive thru testing site and specimen transport. She then went on to secure a position with the Department of Health, during which she has been on a team assisting with all state-operated mass vaccination sites across New York State.
At peak of the pandemic, there were 30 sites open seven days a week in all regions of New York State. She is currently the subject matter expert for the state program known as the Countermeasure Data Management System, which handles patient registration for all mass vaccination sites, as well as their record processing and retention.
Private Practice, Long Island, NY
Dr. Brocavich is currently practicing as a periodontist in Islip, Commack, and Setauket, NY, in multiple private periodontal offices. From a young age, Dr. Brocavich had a passion for science and an interest in dentistry.
She began her undergraduate studies at St. John’s University, and graduated in 2013 with a Bachelor in Science in Toxicology with a minor in Chemistry, and earned a Gold Medal from the College of Pharmacy and Health Sciences. During her time at St. John’s University, she was an active member of Tau Omega Chi and had the opportunity to serve as President in her senior year.
Upon graduation, Dr. Brocavich continued her studies at Stony Brook School of Dental Medicine, where she earned her Doctor of Dental Surgery in 2017. She continued her postdoctoral training at Stony Brook’s Advanced Education Program in Periodontics, where she earned her certificate in Periodontics and Implant Dentistry in 2020. Dr. Brocavich also earned her Master of Science with a focus in Oral Biology and Pathology while completing her specialty certificate. Her research focused on bone regeneration of a novel nanoparticle scaffold in craniomaxillofacial defects.
As a periodontist, Dr. Brocavich provides nonsurgical and surgical treatment for the treatment of gingival and periodontal diseases. She also replaces missing teeth through the placement of dental implants.
Date: Tuesday, October 27, 2020Time: 5–6:30 p.m. Click here for Program PDF
The event was sponsored by the Office of the Dean in the College of Pharmacy and Health Sciences and Tau Omega Chi. It was supported, in part, by the Society of Toxicology (SOT) through the Mid-Atlantic SOT Regional Chapter.
Associate Toxicology Specialist
Shiseido Americas Innovation Center
Ms. Habeeb is currently employed as an Associate Toxicology Specialist at Shiseido Americas Innovation Center. She began her academic career at St. John’s University and became very involved in organizations on campus such as Women in Leadership, Global Medical Brigades, Delta Phi Epsilon, and Tau Omega Chi. She also served as an Orientation Leader at New Student Orientation. She earned her Bachelor of Science degree in Toxicology with a minor in Chemistry in 2016 and continued at St. John’s to pursue her Master of Science degree in Toxicology.
During her graduate years, she was fortunate to gain experience as a teaching assistant. She completed her thesis research work under the mentorship of Jeanette C. Perron, Ph.D. Her efforts focused on identifying the role of bone morphogenetic protein in alcohol toxicity in an overarching project mimicking the clinical model of Fetal Alcohol Syndrome. She defended her thesis in 2019.
Working since 2018 at her current position at Shiseido, Ms. Habeeb has been responsible for reviewing ingredients in final cosmetic formulas and ensuring they are safe for consumer use. Additionally, she monitors clinical studies to ensure they are running according to protocol and analyzes data to ensure clean results. Shiseido has also been supportive of her passion to keep active in the research field and as such, she was able to present some collaborative research with Shiseido and other labs across international meetings such as Eurotox and the Society of Toxicology.
Michigan Department of Health and Human Services (MDHHS)
Ms. Kallakuri is a Toxicologist in the Toxicology and Assessment section at the Michigan Department of Health and Human Services. In her role, Ms. Kallakuri leads the toxicology review of Perfluoroalkyl and Polyfluoroalkyl Substance sites, Agency for Toxic Substances and Disease Registry sites, the National Priorities List, and other sites of environmental contamination where real or perceived exposure to hazardous substances potentially threatens public health. She is responsible for evaluating environmental data, providing technical support for human health risk assessment, and determining whether a public health hazard exists. As part of her job, Ms. Kallakuri collaborates with other federal, state, and local health departments, as well as regulatory agencies, and interacts with the public via meetings, telephone conversations, and field visits, responding to community health concerns.
Ms. Kallakuri earned her Master of Science degree in Toxicology in 2015 from St. John’s University. Prior to her current position, Ms. Kallakuri was employed at L’Oréal USA Research and Innovation as a toxicologist from 2015 to 2017. During that time, she evaluated the toxicity of chemical ingredients in hair products to ensure product safety of finished formulations.
Director, Occupational Toxicology
Dr. Nagavally is the Director of Occupational Toxicology at Mylan Inc. He has a Bachelor of Science degree in Pharmacy, and a Master of Science degree in Toxicology and a Ph.D. from St. John’s University. He is also an American Board of Toxicology-certified toxicologist.
Dr. Nagavally joined Mylan after completing his Ph.D. in 2015 and leads the occupational toxicology function. He provides toxicology and risk assessment expertise to support Global Environment, Health and Safety initiatives concerning research and development and manufacturing decisions regarding Mylan products. As the subject matter expert for occupational toxicology, he collaborates with various stakeholders across the company. He is a key contributor supporting antimicrobial resistance, pharmaceuticals in environment initiatives, and an industrial hygiene function for Mylan.
Westchester County Department of Laboratories and Research
Division of Forensic Toxicology
Dr. Placido-Weber is currently an Assistant Toxicologist at the Westchester County Department of Laboratories and Research, Division of Forensic Toxicology. She received her bachelor’s degree in Chemistry from Fairfield University in 2004. She then went on to obtain her master’s degree in Toxicology from St. John’s under the tutelage of S. William Zito, Ph.D., Senior Associate Dean and Professor, and continued in the same laboratory to earn her Ph.D. in Pharmaceutical Sciences with a specialization in Toxicology.
While pursuing her graduate degrees, Dr. Placido-Weber was a teaching and doctoral fellow, which she cites as one of the most rewarding experiences of her professional career. As a graduate student, she was actively involved in the Mid-Atlantic Regional Chapter of the Society of Toxicology, as well as the Society of Toxicology. She enjoys mentoring junior scientists in toxicology as she helps them achieve their career goals.
In her current role, Dr. Placido-Weber is responsible for the extraction of postmortem and DUI (Driving Under the Influence) biological samples for screening and confirmation of licit and illicit drugs, as well as ethanol quantitation. She is highly proficient in analytical methods of analysis, such as Gas Chromatography/Mass Spectrometry (GC/MS) and Liquid Chromatography/Mass Spectrometry (LC/MS).
Prior to working for Westchester County, Dr. Placido-Weber was previously employed by Revlon Consumer Products Corporation as a Toxicologist. She performed risk assessments of cosmetic raw materials and final formulations, reviewed clinical data of safety-in-use studies, and contributed to the international product registration of cosmetic products. She was also a liaison between Product Development and the Product Safety teams, speaking to her ability to collaborate successfully toward common goals.
Lead of Regulatory Affairs
City of Hope, Duarte, CA
Dr. Sukhija is the Lead of Regulatory Affairs within the clinical trials office at the City of Hope, a National Cancer Institute-designated comprehensive cancer center. She is a registered pharmacist, and earned a Bachelor of Science degree in Pharmacy from the University of Mumbai in India and a master’s degree and a Ph.D. in Pharmacology from St. John’s University.
Dr. Sukhija is also a SOCRA certified Clinical Research Associate. She has a broad background in the pharmacology of drugs and medicinal sciences, with specific training and expertise in key research areas of pediatric cancer clinical research. During her career, she has worked for Charles R. Drew University, Children’s Hospital Los Angeles, and most recently, City of Hope, in field of clinical research since 2011 at different capacities. She has experience in working over thousands of clinical trials, including studies conducted by consortia, sponsors, and in-house investigators.
She has also collaborated with investigators on grant applications and Institutional Review Board (IRB) submissions at both the clinical and bench research levels. Dr. Sukhija has expertise in US Food and Drug Administration submissions for investigational new drug studies, and provides guidance for the submission of studies to the IRB.
Date: September 22, 2022Time: 5 p.m. ESTLocation: VirtualRegistration: Required, please RSVP via this linkProgram
Arun Kumar, Ph.D. ’17GP is an Assistant Professor in the division of Pharmacy Practice and Administrative Sciences at James L. Winkle College of Pharmacy at the University of Cincinnati.
He completed his Ph.D. at the University of Minnesota, Twin Cities, in the pharmacoepidemiology discipline in 2021. Before his Ph.D., he earned an M.S. in Pharmacy Administration in 2017 at St. John’s University.
Dr. Kumar’s research work includes the assessment of the safety and effectiveness of medications used in cardiovascular diseases in the real-world population. Broadly, his research work involves the use of large secondary databases with the application of advanced statistical and epidemiologic methods to assess causal relationships. His research interests also encompass the application of health economics principles for informed decision-making by health-care providers.
Uzma is a Ph.D. student in the Pharmaceutical Health Services Research program at the University of Maryland, Baltimore. She is a graduate student researcher under the supervision of Zafar Zafari, Ph.D., and Danya Qato, Ph.D., Pharm.D., MPH.
Uzma earned her master’s degree in Pharmacy Administration at St. John’s University. Before moving to the United States, she completed her bachelors’ and master’s degrees in Pharmacy with a specialization in Pharmacology at Mumbai University, India.
Uzma’s master’s thesis examines the economic and humanistic burden associated with undiagnosed depression in the Type-2 diabetes population. The role of various mental health conditions and their impact on patients’ overall health quality has always been an interest. During her Ph.D., exposure to research projects related to opioid use disorder and simulation modeling to predict the associated health outcomes has now developed her interests in substance use disorders and machine learning. Her broad research goal is to provide health-care decision-makers the tools to assess the gaps in health-care services delivery and help achieve accessible, affordable, equitable, and good quality patient care.
During her time at St. John’s, she served as the President of the ISPOR student chapter and as a member of the Chapter Development and Survey and Evaluation Committee in the internationally recognized ISPOR Student Network. She currently serves as the University of Maryland ISPOR student chapter President. Uzma likes to listen to music, watch movies, paint, try different coffee shops, and hang out with friends in her spare time.
Young Shin ’19Pharm.D., ’21GP is a first-year Ph.D. student at the University of Cincinnati where she studies Health Outcomes. Her interest in health economics outcomes research began during the latter end of pharmacy school when she was given an opportunity to work on a research project in patient-reported outcomes that was named a research award finalist at the International Society for Pharmacoeconomics and Outcomes Research, Inc.’s Annual Conference.
Inspired by this experience, she pursued her postgraduate education at St. John’s University and the University of Cincinnati, conducting research in cost-effectiveness analysis with a focus on cardiovascular diseases. Her current research work and interests include economic modeling, decision analysis, claims data, and pharmacoepidemiology.
Young aspires to continue her work in the pharmaceutical industry. When she is not too busy reading about acute coronary syndrome and antiplatelet drugs, she enjoys reading books and traveling.